Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains

NCT02968758 · View on ClinicalTrials.gov ↗

Study Summary

The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method considered as gold standard for detection of toxigenic Clostridium difficile in stool specimens.

Interventions

  • DEVICE Comparison between GenePOC PCR and Reference Method

Study Locations (7)

Indiana

  • Wishard Health Services — Indianapolis

Maryland

  • John Hopkins University School of Medicine — Baltimore

Michigan

  • Detroit Medical Center University Laboratories — Detroit

New Mexico

  • Tricore Laboratory University of New Mexico — Albuquerque

Wisconsin

  • Medical College of Wisconsin — Milwaukee

Ontario

  • Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex — Toronto

Quebec

  • McGill University Health Centre — Montreal

Trial Details

FieldValue
Enrollment Target 2,461 participants
Start Date 2017-02-06
Est. Completion 2017-08-10
Phase NA

Sponsor

Meridian Bioscience

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02968758

The ClinicalTrials.gov registry entry for NCT02968758 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,461 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 1 intervention — of which Comparison between GenePOC PCR and Reference Method is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02968758 reports 7 study locations spanning 7 distinct geographic areas — top geographies include Indiana, Maryland, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02968758 about?

NCT02968758 is a clinical study titled "Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains". The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method consid...

What is the current status of trial NCT02968758?

This trial is currently completed. It is a NA study. The enrollment target is 2,461 participants. The study started on 2017-02-06. Estimated completion is 2017-08-10.

What conditions does trial NCT02968758 study?

This clinical trial studies the following conditions: Clostridium Difficile Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02968758?

The interventions under investigation include: Comparison between GenePOC PCR and Reference Method (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02968758?

This trial is sponsored by Meridian Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02968758 being conducted?

This trial has 7 study locations across Indiana, Maryland, Michigan, New Mexico, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial